Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-27), Xeris Biopharma Holdings's Beta is 0.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xeris Biopharma Holdings's Beta
For the Biotechnology subindustry, Xeris Biopharma Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's Beta Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Beta distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Beta falls into.
Xeris Biopharma Holdings Beta Calculation
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Xeris Biopharma Holdings Beta Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 